Thalys Medical Technology Group Inc. (603716.SS)
CNY 9.69
(-3.77%)
CNY 9.69
(-3.77%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.05 Billion CNY | -26.79% |
| 2022 | 1.43 Billion CNY | -11.48% |
| 2021 | 1.62 Billion CNY | 15.94% |
| 2020 | 1.39 Billion CNY | 58.7% |
| 2019 | 881.51 Million CNY | 27.68% |
| 2018 | 690.42 Million CNY | 103.96% |
| 2017 | 338.5 Million CNY | 101.76% |
| 2016 | 167.77 Million CNY | 35.29% |
| 2015 | 124.01 Million CNY | 47.84% |
| 2014 | 83.88 Million CNY | 68.28% |
| 2013 | 49.84 Million CNY | 12.0% |
| 2012 | 44.5 Million CNY | 124.72% |
| 2011 | 19.8 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.09 Billion CNY | 0.95% |
| 2024 Q3 | 1.1 Billion CNY | 2.05% |
| 2024 Q1 | 1.08 Billion CNY | 2.83% |
| 2023 Q1 | 1.29 Billion CNY | -9.67% |
| 2023 FY | 1.05 Billion CNY | -26.79% |
| 2023 Q4 | 1.05 Billion CNY | -16.92% |
| 2023 Q3 | 1.26 Billion CNY | 5.28% |
| 2023 Q2 | 1.2 Billion CNY | -7.34% |
| 2022 Q4 | 1.43 Billion CNY | -3.16% |
| 2022 Q3 | 1.48 Billion CNY | -7.32% |
| 2022 Q1 | 1.54 Billion CNY | -5.01% |
| 2022 Q2 | 1.59 Billion CNY | 3.83% |
| 2022 FY | 1.43 Billion CNY | -11.48% |
| 2021 Q2 | 1.42 Billion CNY | -2.22% |
| 2021 Q3 | 1.46 Billion CNY | 2.84% |
| 2021 Q4 | 1.62 Billion CNY | 11.06% |
| 2021 Q1 | 1.45 Billion CNY | 3.81% |
| 2021 FY | 1.62 Billion CNY | 15.94% |
| 2020 Q1 | 1.08 Billion CNY | 23.03% |
| 2020 FY | 1.39 Billion CNY | 58.7% |
| 2020 Q3 | 1.43 Billion CNY | 43.98% |
| 2020 Q2 | 999.98 Million CNY | -7.79% |
| 2020 Q4 | 1.39 Billion CNY | -2.84% |
| 2019 FY | 881.51 Million CNY | 27.68% |
| 2019 Q4 | 881.51 Million CNY | 2.23% |
| 2019 Q3 | 862.32 Million CNY | -3.76% |
| 2019 Q2 | 896.03 Million CNY | 6.92% |
| 2019 Q1 | 838.03 Million CNY | 21.38% |
| 2018 Q2 | 567.18 Million CNY | 41.27% |
| 2018 Q1 | 401.48 Million CNY | 18.6% |
| 2018 Q3 | 582.73 Million CNY | 2.74% |
| 2018 FY | 690.42 Million CNY | 103.96% |
| 2018 Q4 | 690.42 Million CNY | 18.48% |
| 2017 Q3 | 296.27 Million CNY | 58.6% |
| 2017 FY | 338.5 Million CNY | 101.76% |
| 2017 Q4 | 338.5 Million CNY | 14.25% |
| 2017 Q2 | 186.8 Million CNY | 19.61% |
| 2017 Q1 | 156.18 Million CNY | -6.91% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 FY | 167.77 Million CNY | 35.29% |
| 2016 Q4 | 167.77 Million CNY | -4.72% |
| 2016 Q2 | 150.35 Million CNY | 0.0% |
| 2016 Q3 | 176.09 Million CNY | 17.12% |
| 2015 Q4 | 124.01 Million CNY | 0.0% |
| 2015 FY | 124.01 Million CNY | 47.84% |
| 2014 FY | 83.88 Million CNY | 68.28% |
| 2013 FY | 49.84 Million CNY | 12.0% |
| 2012 FY | 44.5 Million CNY | 124.72% |
| 2011 FY | 19.8 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 6.85 Billion CNY | 84.656% |
| Joinn Laboratories(China)Co.,Ltd. | 85.79 Million CNY | -1125.193% |
| WuXi AppTec Co., Ltd. | 5.75 Billion CNY | 81.738% |
| Autobio Diagnostics Co., Ltd. | 1.03 Billion CNY | -1.247% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 578.98 Million CNY | -81.549% |
| Chemclin Diagnostics Co., Ltd. | 234.6 Million CNY | -348.04% |